CZ285522B6 - Farmaceutický prostředek pro snížení koncentrace glukosy v krvi - Google Patents

Farmaceutický prostředek pro snížení koncentrace glukosy v krvi

Info

Publication number
CZ285522B6
CZ285522B6 CZ941520A CZ152094A CZ285522B6 CZ 285522 B6 CZ285522 B6 CZ 285522B6 CZ 941520 A CZ941520 A CZ 941520A CZ 152094 A CZ152094 A CZ 152094A CZ 285522 B6 CZ285522 B6 CZ 285522B6
Authority
CZ
Czechia
Prior art keywords
blood
medicament
glucose
reducing concentration
pharmaceutically acceptable
Prior art date
Application number
CZ941520A
Other languages
English (en)
Other versions
CZ152094A3 (en
Inventor
George Joseph Cullinan
Terence T. Yen
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CZ152094A3 publication Critical patent/CZ152094A3/cs
Publication of CZ285522B6 publication Critical patent/CZ285522B6/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Farmaceutický prostředek pro snižování koncentrace glukozy v krvi lidí, spočívající v tom, že jako účinnou látku obsahuje amtiestrogenovou sloučeninu ze souboru zahrnujícího 1) triarylethyleny, 2) 2,3-di-aryl-2H- -benzopyrany, 3) 1-aminoalkyl-2-fenylindoly, 4) 2-fenyl-3aroylbenzothiofeny, 5) v poloze 1 substituované 2-aryldihydronaftaleny a 6) benzofurany a jejich farmaceuticky vhodné soli a solváty spolu s farmaceuticky vhodným nosičem, ředidlem nebo excipientem.ŕ
CZ941520A 1993-06-24 1994-06-20 Farmaceutický prostředek pro snížení koncentrace glukosy v krvi CZ285522B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8221893A 1993-06-24 1993-06-24

Publications (2)

Publication Number Publication Date
CZ152094A3 CZ152094A3 (en) 1995-03-15
CZ285522B6 true CZ285522B6 (cs) 1999-08-11

Family

ID=22169806

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ941520A CZ285522B6 (cs) 1993-06-24 1994-06-20 Farmaceutický prostředek pro snížení koncentrace glukosy v krvi

Country Status (23)

Country Link
US (1) US5567713A (cs)
EP (1) EP0635264B1 (cs)
JP (1) JP2886453B2 (cs)
KR (1) KR100325034B1 (cs)
CN (1) CN1086576C (cs)
AT (1) ATE157869T1 (cs)
AU (1) AU669627B2 (cs)
CA (1) CA2126400A1 (cs)
CZ (1) CZ285522B6 (cs)
DE (1) DE69405491T2 (cs)
DK (1) DK0635264T3 (cs)
ES (1) ES2105525T3 (cs)
GR (1) GR3025315T3 (cs)
HU (1) HUT75253A (cs)
IL (1) IL110052A (cs)
NO (1) NO312398B1 (cs)
NZ (1) NZ260790A (cs)
PH (1) PH30490A (cs)
PL (1) PL181025B1 (cs)
RU (1) RU2132682C1 (cs)
TW (1) TW275584B (cs)
UA (1) UA34441C2 (cs)
ZA (1) ZA944377B (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US6391892B1 (en) * 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
JP2000506885A (ja) * 1996-03-19 2000-06-06 イーライ・リリー・アンド・カンパニー 3―[4―(2―アミノエトキシ)ベンゾイル]―2―アリール―6―ヒドロキシベンゾ[b]チオフェンの合成
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
HU230543B1 (hu) * 1999-07-06 2016-11-28 Endorecherche, Inc. Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények
WO2001026651A2 (en) * 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US20090054473A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011007882A1 (ja) * 2009-07-16 2011-01-20 国立大学法人九州大学 インスリン産生細胞誘導剤、グルコース取込み促進剤および糖尿病または糖尿病合併症の治療薬
DK2580210T5 (en) 2010-06-10 2017-06-19 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
WO2018027175A1 (en) * 2016-08-04 2018-02-08 University Of Iowa Research Foundation Use of swell1 inhibitors and modulators to treat type 2 diabetes and obesity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
BE637389A (cs) * 1962-09-13
US4323707A (en) * 1975-10-28 1982-04-06 Eli Lilly And Company Antifertility compounds
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4400543A (en) * 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE69023906T2 (de) * 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤

Also Published As

Publication number Publication date
RU94022479A (ru) 1997-03-20
KR100325034B1 (ko) 2002-08-21
NO942363L (no) 1994-12-27
GR3025315T3 (en) 1998-02-27
ATE157869T1 (de) 1997-09-15
AU669627B2 (en) 1996-06-13
EP0635264A2 (en) 1995-01-25
ES2105525T3 (es) 1997-10-16
EP0635264A3 (en) 1995-04-12
RU2132682C1 (ru) 1999-07-10
NZ260790A (en) 1997-06-24
EP0635264B1 (en) 1997-09-10
DE69405491T2 (de) 1998-02-19
PL181025B1 (pl) 2001-05-31
PL303937A1 (en) 1995-01-09
JPH0748252A (ja) 1995-02-21
TW275584B (cs) 1996-05-11
HUT75253A (en) 1997-05-28
ZA944377B (en) 1995-12-20
CZ152094A3 (en) 1995-03-15
JP2886453B2 (ja) 1999-04-26
PH30490A (en) 1997-05-28
NO942363D0 (cs) 1994-06-21
CN1086576C (zh) 2002-06-26
DK0635264T3 (da) 1997-10-20
IL110052A0 (en) 1994-10-07
UA34441C2 (uk) 2001-03-15
KR950000145A (ko) 1995-01-03
AU6488294A (en) 1995-01-05
NO312398B1 (no) 2002-05-06
CN1100933A (zh) 1995-04-05
IL110052A (en) 2001-04-30
HU9401904D0 (en) 1994-09-28
US5567713A (en) 1996-10-22
DE69405491D1 (de) 1997-10-16
CA2126400A1 (en) 1994-12-25

Similar Documents

Publication Publication Date Title
CZ285522B6 (cs) Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
DE3668892D1 (en) Hypoglycemische thiazolidinedione.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
EP0850648A3 (en) Combination of thrombolytically active proteins and anticoagulants and uses thereof
GR3007202T3 (cs)
AU2711295A (en) Combination treatment for inhibiting bone loss
HU9301253D0 (en) Medical preparative applicable for treatment of enlarged time of coagulation
HU910979D0 (en) Process for the prodiction of medical preparations with n-neuropeptide-antagonistic effect, containing guanidine derivatives
ITBO930070A0 (it) Tavolo porta-paziente per l'effettuazione di esami medici.
ATE239474T1 (de) Verwendung von levobupivacain
CA2041417A1 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
SE8804628D0 (sv) New compounds
AU6932691A (en) Administration method of antithrombin
RS52011B (sr) Nova primena derivata taksoida
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
AU8687391A (en) Lithium treatment
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
ATE70445T1 (de) Pharmazeutische praeparate.
AU3401093A (en) Therapeutic agent for threatened abortion
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
NO890997D0 (no) Applikator for hudrensemiddel, hudpleiemiddel og medisinsk salve.
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
EP0227356A3 (en) The use of depogen in the treatment of restricted blood circulation
GR3015107T3 (en) Use of zofenopril for the preparation of drugs against rheumatoid arthritis.
SE9602262D0 (sv) New use of derivatives of cystine

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20040620